Exploring exhaled volatile organic compounds as potential biomarkers in anti-MDA5 antibody-positive interstitial lung disease
- PMID: 40102365
- DOI: 10.1007/s11010-025-05249-4
Exploring exhaled volatile organic compounds as potential biomarkers in anti-MDA5 antibody-positive interstitial lung disease
Abstract
Interstitial lung diseases (ILDs) are a group of pulmonary disorders characterized by fibrosis, inflammation, and lung tissue deterioration. Anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated interstitial lung disease (MDA5-ILD), a subtype, is associated with high mortality due to rapid progression and severe lung damage. Volatile organic compounds (VOCs) in exhaled breath, reflecting metabolic changes, have been identified as potential non-invasive biomarkers for various diseases, including respiratory conditions. However, their role in MDA5-ILD has not been extensively studied. This retrospective cohort study included 45 exhaled breath samples from 19 ILD patients, with 31 samples from 9 patients with MDA5-ILD and 10 samples from 7 patients with non-MDA5-ILD. VOCs were collected using thermal desorption tubes and analyzed via gas chromatography-mass spectrometry (GC-MS). Clinical data, including the APACHE II score, were integrated with VOC profiles. Two logistic regression models were developed: Model 1 based on 11 clinical indicators, and Model 2 integrating 11 clinical indicators with 5 VOC features. Model performance was evaluated using receiver operating characteristic (ROC) curve analysis, sensitivity, specificity, and accuracy metrics. Five VOCs-N-(2-Aziridinyl)ethanamine, Cyclohexanone, Nonanal, Dodecamethylcyclohexasiloxane, and 4-Methyltetradecane-were identified as significant biomarkers distinguishing MDA5-ILD from non-MDA5-ILD. Model 2, which integrated VOC data, outperformed Model 1, achieving an area under the curve (AUC) of 0.93 compared to 0.70. Model 2 also demonstrated enhanced accuracy (84.6% vs. 76.9%), specificity (66.7% vs. 33.3%), precision (90.0% vs. 81.8%), and F1-score (90.0% vs. 85.7%). Additionally, 1,3-Pentadiene and 3-Methylundecane were identified as potential markers of disease severity, with 1,3-Pentadiene negatively correlating and 3-Methylundecane positively correlating with both APACHE II scores and creatinine levels. VOCs in exhaled breath significantly enhance the diagnostic sensitivity and accuracy for detecting MDA5-ILD. In addition, VOCs show promise as disease severity markers, potentially aiding in the assessment of disease severity and progression. While the integration of VOCs holds great potential for improving diagnostic performance, further validation through larger, multicenter studies is necessary.
Keywords: Biomarker; Exhaled breath analysis; ILD; MDA5; VOC.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: This study received ethical approval from the Medical Ethics Committee of Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology (Ethical approval number: TJ-IRB20231205), with all participants providing written informed consent prior to inclusion. Consent for publication: Not applicable.
Similar articles
-
Mortality Risk Prediction in Patients With Antimelanoma Differentiation-Associated, Gene 5 Antibody-Positive, Dermatomyositis-Associated Interstitial Lung Disease: Algorithm Development and Validation.J Med Internet Res. 2025 Feb 5;27:e62836. doi: 10.2196/62836. J Med Internet Res. 2025. PMID: 39908093 Free PMC article.
-
Diagnostic significance of carcinoembryonic antigen and anti-MDA5 antibodies in polymyositis/dermatomyositis-associated rapidly progressive interstitial lung disease.Med Clin (Barc). 2025 Sep;165(3):107048. doi: 10.1016/j.medcli.2025.107048. Epub 2025 Jun 13. Med Clin (Barc). 2025. PMID: 40516211 English, Spanish.
-
[A study of differences in the course of anti-MDA5-positive dermatomyositis and early diagnosis of rapidly progressive interstitial lung disease].Zhonghua Jie He He Hu Xi Za Zhi. 2025 Aug 12;48(8):726-731. doi: 10.3760/cma.j.cn112147-20241229-00761. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 40764133 Chinese.
-
Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review.Respir Res. 2012 Dec 21;13(1):117. doi: 10.1186/1465-9921-13-117. Respir Res. 2012. PMID: 23259710 Free PMC article.
-
Breath based volatile organic compounds in the detection of breast, lung, and colorectal cancers: A systematic review.Cancer Biomark. 2017 Dec 12;21(1):29-39. doi: 10.3233/CBM-170177. Cancer Biomark. 2017. PMID: 29060925
References
-
- Travis WD, Costabel U, Hansell DM et al (2013) An official American thoracic society/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733–748. https://doi.org/10.1164/rccm.201308-1483ST - DOI - PubMed - PMC
-
- Fathi M, Dastmalchi M, Rasmussen E et al (2004) Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 63:297–301. https://doi.org/10.1136/ard.2003.006122 - DOI - PubMed - PMC
-
- Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280:8–23. https://doi.org/10.1111/joim.12451 - DOI - PubMed
-
- Dias Junior AG, Sampaio NG, Rehwinkel J (2019) A balancing act: MDA5 in antiviral immunity and autoinflammation. Trends Microbiol 27:75–85. https://doi.org/10.1016/j.tim.2018.08.007 - DOI - PubMed
-
- Bhandari S, Zickuhr L, Baral MR et al (2024) A review of MDA-5 dermatomyositis and associated interstitial lung disease. Rheumato 4:33–48. https://doi.org/10.3390/rheumato4010004 - DOI
MeSH terms
Substances
Grants and funding
- 2023AFB179/Hubei Provincial Natural Science Foundation of China
- 62275096/National Natural Science Foundation of China
- 82170081/National Natural Science Foundation of China
- 2023JCYJ046/Interdisciplinary Research Program of Huazhong University of Science and Technology
- 2024BAB099/Hubei Provincial Science and Technology Program
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous